Gregory William Endres
23Patents
4h-index
30Co-inventors
63Inventor score
Filing activity: Sep 11, 2000 → Jun 9, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6410622B1 | Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable therefor | Chemistry; Metallurgy | 20 | Expired |
| US9180116B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 6 | Active |
| US9440919B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | Human Necessities | 4 | Active |
| US9487478B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 4 | Active |
| US9701630B2 | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions | Human Necessities | 2 | Active |
| US9890104B2 | Amine salts of a prostacyclin analog | Chemistry; Metallurgy | 1 | Active |
| US8536185B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | Chemistry; Metallurgy | 1 | Active |
| US9908834B2 | Methods of synthesizing a prostacyclin analog | Chemistry; Metallurgy | 1 | Active |
| US10729810B2 | Methods, systems, and compositions for promoting bone growth | Human Necessities | 0 | Active |
| US8680327B2 | Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites | Chemistry; Metallurgy | 0 | Active |
| US9676712B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US11884624B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US8450326B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | General | 0 | Revoked |
| US9120820B2 | Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins | Physics | 0 | Active |
| US8063240B2 | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions | Human Necessities | 0 | Active |
| US12019002B2 | Ready-to-extract platforms for chemical analysis and quantification of unknown samples using spiked matrix standards | Physics | 0 | Active |
| US10155716B2 | Amine salts of a prostacyclin analog | Chemistry; Metallurgy | 0 | Active |
| US11066361B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US9126973B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | Chemistry; Metallurgy | 0 | Active |
| US10450257B2 | Methods of synthesizing a prostacyclin analog | Chemistry; Metallurgy | 0 | Active |
| US9688627B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Chemistry; Metallurgy | 0 | Active |
| US10556862B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | Human Necessities | 0 | Active |
| US8440417B2 | Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.